rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Targeted Interference with Signal Transduction Events
  name:
    name part: Groner, Bernd.
    role:
      role term: editor.
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: gw
    date issued: 2007
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: IX, 188 p. online resource.
  abstract: Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.
  table of contents: Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy -- Identifying Critical Signaling Molecules for the Treatment of Cancer -- Tyrosine Kinase Inhibitors and Cancer Therapy -- Targeting ERBB Receptors in Cancer -- Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approaches -- Inhibition of the TGF-? Signaling Pathway in Tumor Cells -- The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition -- The Ras Signalling Pathway as a Target in Cancer Therapy -- The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment -- Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events.
  note: edited by Bernd Groner.
  subject:
    topic: Medicine
  subject:
    topic: Cancer research
  subject:
    topic: Molecular biology
  subject:
    topic: Oncology
  subject:
    topic: Biomedicine
  subject:
    topic: Cancer Research
  subject:
    topic: Oncology
  subject:
    topic: Molecular Medicine
  classification: RC261-271
  classification: 614.5999
  related item:
    title info:
      title: Springer eBooks
  related item:
    title info:
      title: Resent Results in Cancer Research, 172
  identifier: 9783540312093
  identifier: http://dx.doi.org/10.1007/978-3-540-31209-3
  record info:
    record creation date: 100301
    record change date: 20151201021715.0
    record identifier: 978-3-540-31209-3